HOUSTON--(BUSINESS WIRE)--Aug. 30, 2006--Power3 Medical Products, Inc. (OTCBB: PWRM), announced today that preliminary results of tests using biomarkers it discovered have shown greater than 90% sensitivity in identifying patients with Alzheimer’s disease. A leading proteomics company, Power3 Medical (www.Power3Medical.com) is developing proteomic testing and biomarker discovery methods for early detection, monitoring, and staging of a broad range of diseases, including Alzheimer’s, Parkinson’s, and ALS (Lou Gehrig’s disease).
